Paul Marcun - Coloplast A/S Senior Vice President Emerging Markets
| CLPBF Stock | USD 109.13 0.00 0.00% |
President
Mr. Paul Marcun was appointed Executive Vice President Chronic Care, Member of the Executive Management at Coloplast AS, effective as of midJanuary 2019. He was Senior Vice President, Emerging Markets at the Company from 2015 till 2018. He holds a Bachelor of Veterinary Science from the University of Melbourne and a MBA in Corporationrationrate Finance Marketing from Sydney University of Technology. since 2019.
| Age | 56 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 45 49 11 11 11 |
| Web | https://www.coloplast.com |
Coloplast A/S Management Efficiency
The company has return on total asset (ROA) of 0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast A/S's management efficiency ratios could be used to measure how well Coloplast A/S manages its routine affairs as well as how well it operates its assets and liabilities.Coloplast AS has accumulated 16.36 B in total debt with debt to equity ratio (D/E) of 2.83, implying the company greatly relies on financing operations through barrowing. Coloplast A/S has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Coloplast A/S until it has trouble settling it off, either with new capital or with free cash flow. So, Coloplast A/S's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Coloplast A/S sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Coloplast to invest in growth at high rates of return. When we think about Coloplast A/S's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Simon Campion | Becton Dickinson and | 49 | |
| Christopher Reidy | Becton Dickinson and | 64 | |
| Roland Goette | Becton Dickinson and | 58 | |
| Alexandre Conroy | Becton Dickinson and | 57 | |
| Betty Larson | Becton Dickinson and | 44 | |
| Patrick Kaltenbach | Becton Dickinson and | 56 | |
| Anders LonningSkovgaard | Coloplast A | 51 | |
| Thomas Spoerel | Becton Dickinson and | 46 | |
| James Borzi | Becton Dickinson and | 49 | |
| Guillaume Daniellot | Straumann Holding AG | 53 | |
| James Lim | Becton Dickinson and | 56 | |
| John DeFord | Becton Dickinson and | 55 | |
| Charles Bodner | Becton Dickinson and | 46 | |
| Nicolai Andersen | Coloplast A | 54 | |
| Alain Morvan | Coloplast A | N/A | |
| Christopher DelOrefice | Becton Dickinson and | 53 | |
| David Hickey | Becton Dickinson and | 60 | |
| Alberto Mas | Becton Dickinson and | 59 | |
| Samrat Khichi | Becton Dickinson and | 53 | |
Management Performance
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 |
Coloplast A/S Leadership Team
Elected by the shareholders, the Coloplast A/S's board of directors comprises two types of representatives: Coloplast A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coloplast. The board's role is to monitor Coloplast A/S's management team and ensure that shareholders' interests are well served. Coloplast A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coloplast A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ellen Bjurgert, VP Relations | ||
| Allan Rasmussen, Executive VP of Global Operations | ||
| Alain Morvan, Senior Vice President Sales Europe | ||
| Thomas Barfod, Director, Employee Representative | ||
| Nicolai Andersen, Senior Vice President Wound Care | ||
| Anders LonningSkovgaard, CFO, Executive Vice President Member of the Executive Management | ||
| Kristian Villumsen, Executive VP of Chronic Care | ||
| Paul Marcun, Senior Vice President Emerging Markets | ||
| Dorthe Ronnau, VP Culture | ||
| Dennis Kaysen, Director Communications |
Coloplast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Coloplast A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 28.84 B | |||
| Shares Outstanding | 194.31 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 25.53 % | |||
| Price To Earning | 37.47 X | |||
| Price To Book | 22.60 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Coloplast Pink Sheet
Coloplast A/S financial ratios help investors to determine whether Coloplast Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast A/S security.